Structure Therapeutics

GPCR

Market cap $1.99B

The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.

Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025

The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.

Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.

The weight-management market is arguably the hottest therapeutic area in the industry right now. Investors seeking to capitalize on the rapid expansion of this niche can turn to established giants like Eli Lilly and Novo Nordisk.

Structure Therapeutics Inc. (NASDAQ:GPCR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Raymond Stevens - CEO & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everyone.

Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts

Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.